Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE1
45 participants
INTERVENTIONAL
2021-12-15
2026-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
0 mg THC, 0 mg myrcene, 0 mg BCP
Placebo
Vaporized Placebo
Low strength THC
5 mg THC, 0 mg myrcene, 0 mg BCP
Low THC
Vaporized THC (5 mg)
Higher strength THC
15 mg THC, 0 mg myrcene, 0 mg BCP
High THC
Vaporized THC (15 mg)
Low strength myrcene
0 mg THC, 0.5 mg myrcene, 0 mg BCP
Low Myrcene
Vaporized Myrcene (0.5 mg)
High strength myrcene
0 mg THC, 12.0 mg myrcene, 0 mg BCP
High Myrcene
Vaporized Myrcene (12.0 mg)
Low strength BCP
0 mg THC, 0 mg myrcene, 0.5 mg BCP
Low Beta-Caryophyllene
Vaporized Beta-Caryophyllene (0.5 mg)
High strength BCP
15 mg THC, 0 mg myrcene, 7.5 mg BCP
High THC
Vaporized THC (15 mg)
High Beta-Caryophyllene
Vaporized Beta-Caryophyllene (7.5 mg)
Low THC + Low myrcene
5 mg THC, 0.5 mg myrcene, 0 mg BCP
Low THC
Vaporized THC (5 mg)
Low Myrcene
Vaporized Myrcene (0.5 mg)
Low THC + High myrcene
5 mg THC, 12.0 mg myrcene, 0 mg BCP
Low THC
Vaporized THC (5 mg)
High Myrcene
Vaporized Myrcene (12.0 mg)
High THC + Low myrcerne
15 mg THC, 0.5 mg myrcene, 0 mg BCP
High THC
Vaporized THC (15 mg)
Low Myrcene
Vaporized Myrcene (0.5 mg)
High THC + High myrcene
15 mg THC, 12.0 mg myrcene, 0 mg BCP
High THC
Vaporized THC (15 mg)
High Myrcene
Vaporized Myrcene (12.0 mg)
Low THC + Low BCP
5 mg THC, 0 mg myrcene, 0.5 mg BCP
Low THC
Vaporized THC (5 mg)
Low Beta-Caryophyllene
Vaporized Beta-Caryophyllene (0.5 mg)
Low THC + High BCP
5 mg THC, 0 mg myrcene, 7.5 mg BCP
Low THC
Vaporized THC (5 mg)
High Beta-Caryophyllene
Vaporized Beta-Caryophyllene (7.5 mg)
High THC + Low BCP
15 mg THC, 0 mg myrcene, 0.5 mg BCP
High THC
Vaporized THC (15 mg)
Low Beta-Caryophyllene
Vaporized Beta-Caryophyllene (0.5 mg)
High THC + High BCP
15 mg THC, 0 mg myrcene, 7.5 mg BCP
High THC
Vaporized THC (15 mg)
High Beta-Caryophyllene
Vaporized Beta-Caryophyllene (7.5 mg)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Low THC
Vaporized THC (5 mg)
High THC
Vaporized THC (15 mg)
Low Myrcene
Vaporized Myrcene (0.5 mg)
High Myrcene
Vaporized Myrcene (12.0 mg)
Low Beta-Caryophyllene
Vaporized Beta-Caryophyllene (0.5 mg)
High Beta-Caryophyllene
Vaporized Beta-Caryophyllene (7.5 mg)
Placebo
Vaporized Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Report non-medical use of cannabis 1-7 days per week over the 1 month prior to screening
* Not currently seeking treatment for cannabis use
* Urine test positive for recent cannabis use
* Have a Body Mass Index from 18.5 - 34kg/m2.
* Able to perform all study procedures
* Must be using a contraceptive method (hormonal or barrier methods)
Exclusion Criteria
* Report using other illicit drugs in the prior 4 weeks
* • If medical history, physical and psychiatric examination, or laboratory tests performed during the screening process not within the normal range and / or reveal any significant illness (e.g., hypertension) as judged by the study physician and to put the participant at greater risk of experiencing adverse events due to completion of study procedures.
* Current licit use of cannabis primarily for medical purposes, prescription analgesics, or any medications that may affect study outcomes
* Current pain
* Pregnancy is exclusionary due to the possible effects of the study medication on fetal development.
* History of an allergic reaction or adverse reaction to cannabis is exclusionary.
* History of respiratory illness or current respiratory illness
* History of seizure disorder or current seizure disorder
* Insensitivity to the cold water stimulus of the Cold Pressor Test
* Currently enrolled in another research protocol
* Current major Axis 1 disorders (mood, anxiety, or psychotic disorder)
* Not using a contraceptive method (hormonal or barrier methods)
* The evaluating physician reviews all medical assessments along with medical history. Any disorders that might make cannabis administration hazardous are exclusionary.
21 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Center for Complementary and Integrative Health (NCCIH)
NIH
University of California, Los Angeles
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ziva D. Cooper, PhD
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ziva Cooper, PhD
Role: PRINCIPAL_INVESTIGATOR
University of California, Los Angeles
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California, Los Angeles
Los Angeles, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
19-001519
Identifier Type: -
Identifier Source: org_study_id